{"id":569744,"date":"2026-10-07T15:00:00","date_gmt":"2026-10-07T13:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/un-inhibiteur-de-la-sglt-2-et-ou-un-mimetique-de-lincretine-en-traitement-dappoint\/"},"modified":"2026-10-12T16:51:30","modified_gmt":"2026-10-12T14:51:30","slug":"un-inhibiteur-de-la-sglt-2-et-ou-un-mimetique-de-lincretine-en-traitement-dappoint","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/un-inhibiteur-de-la-sglt-2-et-ou-un-mimetique-de-lincretine-en-traitement-dappoint\/","title":{"rendered":"Un inhibiteur de la SGLT-2 et\/ou un mim\u00e9tique de l&#8217;incr\u00e9tine en traitement d&#8217;appoint ?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>De nos jours, le choix du traitement m\u00e9dicamenteux ne repose plus uniquement sur le<sub>taux initial d&#8217;HbA1c<\/sub>, mais \u00e9galement sur les facteurs de risque ou les comorbidit\u00e9s telles que l&#8217;insuffisance cardiaque, les maladies r\u00e9nales ou l&#8217;ob\u00e9sit\u00e9. En raison d\u2019un b\u00e9n\u00e9fice suppl\u00e9mentaire sur le plan cardior\u00e9nal, les inhibiteurs du SGLT-2 ou les mim\u00e9tiques de l\u2019incr\u00e9tine sont recommand\u00e9s chez de nombreux patients atteints de diab\u00e8te de type 2 en compl\u00e9ment de la metformine. De plus, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que l\u2019association d\u2019inhibiteurs du SGLT-2 et d\u2019imitateurs d\u2019incr\u00e9tines permettait d\u2019obtenir des effets additifs. Le fait qu\u2019un double agoniste GLP-1\/GIP se soit d\u00e9sormais impos\u00e9 dans la pratique parmi ces derniers constitue une optimisation suppl\u00e9mentaire des options th\u00e9rapeutiques.<\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fun-inhibiteur-de-la-sglt-2-et-ou-un-mimetique-de-lincretine-en-traitement-dappoint%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>De nos jours, le choix du traitement m\u00e9dicamenteux ne repose plus uniquement sur letaux initial d&#8217;HbA1c, mais \u00e9galement sur les facteurs de risque ou les comorbidit\u00e9s telles que l&#8217;insuffisance cardiaque,&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fun-inhibiteur-de-la-sglt-2-et-ou-un-mimetique-de-lincretine-en-traitement-dappoint%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":569745,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Diab\u00e8te de type 2 : d'une approche centr\u00e9e sur le glucose \u00e0 une approche cardior\u00e9nale et m\u00e9tabolique","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11378,11404,11527,11531,11434,11535],"tags":[102872,18584,102873,23395,12050,44134,23873,20725,36865,4157,94720,21442,2152,102871,12410,94722,73047,17458,18589,72440,77102],"powerkit_post_featured":[],"class_list":["post-569744","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-cardiologie","category-endocrinologie-et-diabetologie","category-etudes","category-formation-continue","category-nephrologie-fr","category-rapports-de-congres","tag-agoniste-du-glp-1-gip","tag-agoniste-du-recepteur-glp-1","tag-benefice-supplementaire-cardio-renal","tag-dapagliflozine","tag-diabete-de-type-2","tag-empagliflozine","tag-facteurs-de-risque","tag-forxiga-fr","tag-hba1c-fr","tag-insuffisance-cardiaque","tag-jardiance","tag-maladie-renale","tag-metformine","tag-mimetique-de-lincretine","tag-obesite","tag-ozempic","tag-rybelsus-fr","tag-semaglutid-fr","tag-sglt-2-i-fr","tag-tirzepatide-fr","tag-wegovy-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-21 17:08:40","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":569673,"slug":"un-farmaco-della-classe-sglt-2-e-o-un-mimico-dellincretina-come-terapia-aggiuntiva","post_title":"Un farmaco della classe SGLT-2 e\/o un mimico dell\u2019incretina come terapia aggiuntiva?","href":"https:\/\/medizinonline.com\/it\/un-farmaco-della-classe-sglt-2-e-o-un-mimico-dellincretina-come-terapia-aggiuntiva\/"},"pt_PT":{"locale":"pt_PT","id":569679,"slug":"um-inibidor-da-sglt-2-e-ou-um-mimetico-da-incretina-como-tratamento-complementar","post_title":"Um inibidor da SGLT-2 e\/ou um mim\u00e9tico da incretina como tratamento complementar?","href":"https:\/\/medizinonline.com\/pt-pt\/um-inibidor-da-sglt-2-e-ou-um-mimetico-da-incretina-como-tratamento-complementar\/"},"es_ES":{"locale":"es_ES","id":569749,"slug":"un-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario","post_title":"\u00bfUn inhibidor de SGLT-2 y\/o un mim\u00e9tico de la incretina como tratamiento complementario?","href":"https:\/\/medizinonline.com\/es\/un-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/569744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=569744"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/569744\/revisions"}],"predecessor-version":[{"id":569746,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/569744\/revisions\/569746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/569745"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=569744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=569744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=569744"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=569744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}